{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:28Z","timestamp":1791443008045,"version":"4.3.3"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Paliperidone palmitate (PP) is a once\u2010monthly long\u2010acting injectable antipsychotic approved for the treatment of schizophrenia in many countries. To evaluate the different injection\u2010site options, we compared the pharmacokinetic profile of paliperidone after multiple injections of PP 100\u2009mg\u2009eq. (156\u2009mg of PP, equivalent to 100\u2009mg of paliperidone) on days 1, 8, 36, and 64 into the deltoid (n\u2009=\u200924) or gluteal muscle (n\u2009=\u200925) in patients with schizophrenia. After four injections in the deltoid muscle, paliperidone exposure was higher for AUC<jats:sub>\u03c4<\/jats:sub> and C<jats:sub>max<\/jats:sub>, compared with the gluteal muscle (geometric mean AUC<jats:sub>\u03c4<\/jats:sub>\u2010based ratio: 120% [90% CI: 93.1\u2013154.7%], and geometric mean C<jats:sub>max<\/jats:sub>\u2010based ratio: 130% [90% CI: 100.6\u2013168.9%]). The mean [SD] fluctuation index was higher, with a larger interpatient variability, after deltoid\u2010injections (75.9% [30.9%]) than gluteal\u2010injections (58.5% [14.3%]). The median t<jats:sub>max<\/jats:sub> was similar for both sites. PP was generally tolerable in patients, with more favorable local\u2010site tolerability for gluteal\u2010injection. In conclusion, to achieve therapeutic\u2010concentrations quickly, the first\u2010two injections of PP are best administered into the deltoid muscle, whereas thereafter maintenance\u2010injections can be administered either in the deltoid or gluteal muscle.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cpdd.144","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T18:16:08Z","timestamp":1405448168000},"page":"270-278","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia"],"prefix":"10.1002","volume":"4","author":[{"given":"Stefaan","family":"Rossenu","sequence":"first","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Cleton","sequence":"additional","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hough","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vandebosch","sequence":"additional","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Berwaerts","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Eerdekens","sequence":"additional","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Herben","sequence":"additional","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"De Meulder","sequence":"additional","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Remmerie","sequence":"additional","affiliation":[{"name":"Division of Janssen Pharmaceutica NV Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Francetic","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology Clinical Hospital Centre Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxn001"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1105"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(03)00109-3"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.499125"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11208640-000000000-00000"},{"key":"e_1_2_10_7_1","unstructured":"Paliperidone palmitate (Xeplion) prescribing information.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002105\/WC500103317.pdf. Accessed October 7 2013."},{"key":"e_1_2_10_8_1","unstructured":"Paliperidone palmitate (Invega Sustenna) prescribing information.http:\/\/www.invegasustenna.com\/pdf\/invegasustenna\u2010prescribing\u2010info.pdf. Accessed September 16 2013."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02240.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.02.001"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833948fa"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990988"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.79"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181dd3103"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.10.026"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.11.008"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.05.014"},{"key":"e_1_2_10_18_1","first-page":"107","article-title":"A single\u2010dose, open\u2010label, parallel, randomized, dose\u2010proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia","volume":"15","author":"Cleton A","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.04.041"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_10_23_1","volume-title":"ECDEU assessment manual for psychopharmacology, revised, 1976, US Department Health, Education and Welfare Pub. No. (ADM), 76\u2010338","author":"Guy W."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316870-000000000-00000"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197517144"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197609022951006"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.3.2.146"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-26"},{"key":"e_1_2_10_29_1","first-page":"1","article-title":"A randomized trial of paliperidone palmitate and risperidone long\u2010acting injectable in schizophrenia","author":"Fleischhacker WW","year":"2011","journal-title":"Int J Neuropsychopharmacol."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110372817"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.144","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:09:14Z","timestamp":1696637354000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/cpdd.144"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.144","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,28]]}}}